Risk of Parkinson disease in women: Effect of reproductive characteristics

Neurology

Volumn 62, Issue 11, 2004, Pages 2010-2014

  Ragonese, P ^a   D'Amelio, M ^a   Salemi, G ^a   Aridon, P ^a   Gammino, M ^a   Epifanio, A ^b   Morgante, L ^b   Savettieri, G ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ESTROGEN RELEASE; FEMALE; FERTILITY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PREGNANCY; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL ANALYSIS;

EID: 2942622651     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.62.11.2010     Document Type: Article

References (50)

1. Woolley CS. Effects of estrogen in the CNS. Curr Opin Neurobiol 1999; 9:349-354.
2. Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog Neurobiol 2001;63:29-60.
3. Kuppers E, Ivanova T, Karolczak M, Lazarov N, Beyer C. Classical and nonclassical estrogen action in the developing midbrain. Horm Behav 2001;40:196-202.
4. Belcher SM, Zsarnovszky A. Estrogenic actions in the brain: estrogen, phytoestrogens, and rapid intracellular signaling mechanisms. J Pharmacol Exp Ther 2001;299:408-414.
5. Wright CE, Sisson TL, Ichpurani AK, Peters GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997;37:520-525.
6. Shulman LM. Is there a connection between estrogen and Parkinson's disease? Parkinsonism 2002;8:289-295.
7. Dluzen D, Ramirez VD. In vitro dopamine from rat striatum: diurnal rhythm and its modification by estrous cycle. Neuroendocrinology 1985; 41:97-100.
8. Di Paolo T, Falardeau P, Morissette M. Striatal D-2 dopamine agonist binding sites fluctuate during the rat estrous cycle. Life Sci 1988;43: 665-672.
9. Becker JB. Direct effect of 17β-estradiol on striatum: sex differences in dopamine release. Synapse 1990;5:157-164.
10. Grody WW, Schrader WT, O'Malley BW. Activation, transformation, and subunit structure of steroid hormone receptors. Endocr Rev 1982;3: 141-163.
11. Savouret JF, Misrahi M, Loosfelt H, et al. Molecular and cellular biology of mammalian progesterone receptors. Recent Progr Horm Res 1989;45:65-118.
12. Murdoch FE, Gorski J. The role of ligand in estrogen receptor regulation of gene expression. Mol Cell Endocrinol 1991;78:C103-C108.
13. O'Malley BW, Tsai SY, Bagchi M, Weigel NL, Schrader WT, Tsai MJ. Molecular mechanism of action of a steroid hormone receptor. Recent Prog Horm Res 1991;47:1-24.
14. Brann DW, Hendry LB, Mahesh VB. Emerging diversities in the mechanism of action of steroid hormones. J Steroid Biochem Mol Biol 1995; 52:113-133.
15. Tsai MJ, O'Malley BW. Molecular mechanism of action of steroid/ thyroid receptor superfamily members. Annu Rev Biochem 1994;63: 451-486.
16. Cole P, MacMahon B. Oestrogen fractions during early reproductive life in the etiology of breast cancer. Lancet 1969;1:604-609.
17. Melamed M, Castaño E, Notides AC, Sasson S. Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol 1997;11:1868-1878.
18. Elbaz A, Bower JH, Maraganore DM, et al. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 2002;55:25-31.
19. Bower JH, Maraganore DM, McDonnel SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52:1214-1220.
20. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995;142:820-827.
21. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000;55:1358-1363.
22. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement therapy on early Parkinson's disease. Neurology 1999;52:1417-1421.
23. Marder K, Tang M-X, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998;50: 1141-1143.
24. Morissette M, Di Paolo T. Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. J Neurochem 1993;60:1876-1883.
25. Disshon KA, Dluzen DE. Estrogen as a neuromodulator of MPTP-induced neurotoxicity: effects upon striatal dopamine release. Brain Res 1997;764:9-16.
26. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001;16:830-837.
27. Morgante L, Rocca WA, Di Rosa AE, et al. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. Neurology 1992;42:1901-1907.
28. de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MMB, Maraganore DM. A population perspective on diagnostic criteria for Parkinson's disease. Neurology 1997;48:1277-1281.
29. Schlesselman JJ, Stolley PD. Case-control studies. Design, conduct, analysis. New York: Oxford University Press, 1992.
30. Hankinson SE, Colditz GA, Hunter DJ, et al. Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses' Health Study (United States). Cancer Causes Control 1995;6:217-224.
31. Windham GC, Elkin E, Fenster L, et al. Ovarian hormones in premenopausal women: variation by demographic, reproductive and menstrual cycle characteristics. Epidemiology 2002;13:675-684.
32. Dorgan JF, Reichman ME, Judd JT, et al. Relationship of age and reproductive characteristics with plasma estrogens and androgens in premenopausal women. Cancer Epidemiol Biomarkers Prev 1995;4: 381-386.
33. Bernstein L, Pike MC, Ross RK, Judd HL, Henderson BE. Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. JNCI 1985;74:741-745.
34. Moore JW, Key TJ, Bulbrook RD, et al. Sex hormone binding globulin and risk factors for breast cancer in a population of normal women who had never used exogenous sex hormones. Br J Cancer 1987;56:661-666.
35. Moore JW, Key TJ, Clarck GM, Hoare SA, Allen DS, Wang DY. Sex-hormone-binding globulin and breast cancer risk. Anticancer Res 1987; 7:1039-1047.
36. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyomas in black and white women: ultrasound. Am J Obstet Gynecol 2003;188:100-107.
37. De Leo V, Morgante G, La Marca A, et al. A benefit-risk assessment of medical treatment for uterine leiomyomas. Drug Safety 2002;25:759-779.
38. Steward EA. Uterine fibroids. Lancet 2001;357:293-298.
39. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyomas among premenopausal women by age and race. Obstet Gynecol 1997;90:967-973.
40. Ross RK, Pike MC, Vessey MB, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives [published erratum in Br Med J 1986;293:1027]. Br Med J 1986; 293:359-362.
41. Ross RK, Pike MC, Vessey MB, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives [published erratum in Br Med J 1986;293:1027]. Br Med J 1986; 293:359-362.
42. Parazzini F, La Vecchia C, Negri E, Cecchetti G, Fedele L. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Fertil Steril 1998;72:853-857.
43. Tsang KL, Ho SL, Lo SK. Estrogens improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 2000;54:2292-2298.
44. Bedard P, Langelier P, Villeneuve A. Oestrogens and extrapyramidal system. Lancet 1977;2:1367-1368.
45. Treloar AE. Menarche, menopause, and intervening fecundability. Hum Biol 1974;46:89-107.
46. Bean JA, Leeper JD, Wallace RB, Sherman BM, Jagger H. Variations in the reporting of menstrual histories. Am J Epidemiol 1979;109:181-185.
47. Bosetti C, Tavani A, Negri E, Trichopoulos D, La Vecchia C. Reliability of data on medical condition, menstrual and reproductive history provided by hospital controls. J Clin Epidemiol 2001;54:902-906.
48. Lin SS, Glaser SL, Stewart SL. Reliability of self-reported reproductive factors and childhood social class indicators in a case-control study in women. Ann Epidemiol 2002;12:242-247.
49. Ellenberg JH. Differential postmorbidity mortality in observational studies of risk factors for neurologic disorders. Neuroepidemiology 1994;13:187-194.
50. Morabia A, Costanza MC, and World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. International variability in ages at menarche, first livebirth, and menopause. Am J Epidemiol 1998;148:1195-1205.